Novartis confirms Sandoz spinoff rumors

At long last the moment has arrived — Novartis announced its intention to separate Sandoz, its generics and biosimilars division, into a new publicly traded standalone company
Aug. 25, 2022

At long last the moment has arrived — Novartis announced its intention to separate Sandoz, its generics and biosimilars division, into a new publicly traded standalone company.

Rumors that Novartis was mulling a sale or spinoff of Sandoz have been swirling since last Oct. when the Swiss drugmaker's CEO, Vas Narasimhan, announced a strategic review of the unit to decide if it’s still a good fit with the company’s long-term growth plans. Last month, "people familiar with the matter" leaked to Bloomberg that the spinoff was the likely choice.

Now it's official. The 100% spin-off — armed with a biosimilars pipeline of 15+ molecules — will create Europe's largest generics company by sales.

The standalone Sandoz will be headquartered in Switzerland. The transaction is expected to be completed in the second half of next year.

Sign up for Pharma Manufacturing Newsletters
Get the latest news and updates